What is the difference between Brigatinib and Alectinib? Which one is better?

Brigatinib/Brigatinib (Brigatinib) and aletinib (< /span>Alectinib) are oral anti-tumor drugs and belong to ALK (anaplastic Lymphoma kinase) fusion-positive targeted therapy for non-small cell lung cancer (NSCLC). They have similar mechanisms of action and efficacy, but there are some differences.

1.Drug characteristics:

Brigatinib/Brigatinib: Brigatinib/Brigatinib is a multi-target tyrosine kinase inhibitor (TKI< span>), can inhibit multiple kinases, including ALK, ROS1, FLT3, VEGFR, etc. It can inhibit the growth and spread of tumor cells through the inhibition of multiple signaling pathways.

Aletinib: Aletinib is also an inhibitor of ALK and ROS1, which interferes with the proliferation of tumor cells mainly by inhibiting the activity of these kinases.

2.Clinical efficacy:

Brigatinib/Brigatinib: Brigatinib/Brigatinib< /span>It has shown significant efficacy in the treatment ofALKpositiveNSCLC patients. Clinical trial results show that Brigatinib/Brigatinib can provide longer progression-free survival and overall survival in both first-line and second-line treatments, and reduce the risk of tumor progression.

Alectinib: Alectinib has also shown good efficacy in the treatment of ALK-positive NSCLC patients. Clinical trial data show that alectinib can prolong progression-free survival and overall survival in both first-line and second-line treatments.

3.Resistance mechanism:

Brigatinib/Brigatinib: For some common ALK resistance mutations, such as ALKG1202R and L1196M and other mutations, Brigatinib/Brigatinib has a relatively low inhibitory effect. However, for some ALK resistance mutations, such as ALK’s T790M mutation, brigatinib/bugatinib still shows a certain anti-tumor effect.

Alectinib: Alectinib has shown certain advantages in combating ALK resistance mutations. It has a strong inhibitory effect on some common ALK drug-resistant mutations, such as ALK's G1202R and L1196M mutations.

The choice between Brigatinib/Brigatinib and alectinib should be decided based on the patient's specific circumstances, analysis of resistance mutations, and physician recommendations. There is no clear evidence that which drug is better in all patients. Each patient's disease characteristics and individual differences are unique, and treatment should be individualized based on the patient's specific circumstances.

During the decision-making process, full discussion and evaluation should be conducted with the doctor, taking into account the drug's efficacy, resistance mechanism, side effects, and individual patient characteristics to formulate a treatment plan that is most suitable for the patient.

Brigatinib/Brigatinib has been launched in China and has been included in medical insurance. Since it has just been approved for marketing, patients may not be able to buy it in domestic pharmacies. If you need to purchase it in China, please consult the local pharmacy. However, the price is quite high, more than 10,000 yuan. Foreign Brigatinib/Brigatinib are mainly generic drugs, mainly Bangladeshi and Laos generic drugs. The price of the international version of the Bangladeshi generic drug Yaopin is about 2000yuan, the specification is 90mg*30 tablets; the price of the Laos version of the generic drug is about 600, and the specification is smaller. And the ingredients of domestic original drugs and foreign generic drugs are basically the same.

Aletinib has been launched in China and has been included in medical insurance. Patients can purchase it domestically. Please consult your local pharmacy for specific prices. There are also original drugs and generic drugs abroad. Original drugs are mainly Turkish original drugs, and the price is about 11,000 yuan; generic drugs are mainly Bangladeshi and Laos generic drugs. Bangladeshi generic drugs are about 2,700 yuan, and Laotian generic drugs are about 6,000 yuan.